Executive Summary & Investment Recommendation

This report provides a comprehensive investment analysis of IDEXX Laboratories, Inc. (NASDAQ: IDXX), the global leader in veterinary diagnostics. The core investment thesis is that IDEXX represents a best-in-class, durable compounder whose formidable competitive moat, superior financial profile, and direct alignment with powerful secular tailwinds in pet healthcare justify its premium valuation, despite near-term macroeconomic headwinds. The company’s integrated ecosystem of in-clinic analyzers, reference laboratory services, and practice management software creates exceptionally high switching costs and a virtuous cycle of recurring revenue growth, positioning it to capitalize on the non-discretionary nature of escalating pet care spending for the foreseeable future.

The analysis concludes that recent industry challenges, such as moderating veterinary clinic visit growth and inflationary pressures, have paradoxically highlighted the resilience of IDEXX’s business model. While visit volumes have softened, the company has demonstrated a remarkable ability to drive growth through increased diagnostic utilization per visit, a testament to the “humanization of pets” trend and the rising standard of care. Furthermore, these pressures are accelerating the adoption of IDEXX’s newest, most innovative platforms, which are designed to enhance clinic workflow and productivity—addressing the very pain points its customers are facing.

The company’s financial performance is exceptional, characterized by high-single-digit to low-double-digit organic revenue growth, best-in-class gross and operating margins consistently above 60% and 30% respectively, and robust free cash flow conversion. A highly scalable “razor/razorblade” business model provides significant operating leverage, enabling profits to grow faster than revenue. This is complemented by a shareholder-friendly capital allocation strategy focused on value-accretive share repurchases.

While the stock trades at a premium to the broader market and its direct peers, this valuation is warranted by its superior quality, durability, and growth prospects. The current valuation is in line with the company’s historical averages and reflects its dominant market position, high barriers to entry, and a long runway for growth fueled by a powerful innovation pipeline and international expansion.

I. The IDEXX Ecosystem: A Dominant & Defensible Business Model

IDEXX’s market leadership is built upon a deeply entrenched and highly defensible business model centered on an integrated ecosystem of diagnostics, software, and services. The company operates across four primary segments, with the Companion Animal Group (CAG) serving as the undisputed engine of growth and profitability.¹

Dissecting the Four Core Segments: CAG, Water, LPD, and Other

Companion Animal Group (CAG): This segment is the company’s crown jewel, consistently generating the vast majority of total revenue and profits. It provides a comprehensive suite of products and services to veterinarians for companion animals like dogs, cats, and horses.¹ The CAG segment’s strength lies in its diverse and highly recurring revenue streams, which can be broken down as follows ²:

• CAG Diagnostics Recurring Revenue: This is the most critical component of the business, representing the lifeblood of IDEXX’s financial model. In the second quarter (Q2) of 2025, this sub-segment delivered robust 7% organic growth.³ It consists of:

• IDEXX VetLab® Consumables: This is the “razorblade” revenue derived from the sale of single-use slides, reagents, and cartridges for IDEXX’s proprietary in-clinic diagnostic analyzers (e.g., Catalyst®, ProCyte®). This is the highest-margin and fastest-growing part of the business, posting exceptional 14% organic growth in Q2 2025, which highlights strong and growing utilization of the installed instrument base.⁴
• Reference Laboratory Diagnostic and Consulting Services: IDEXX operates a global network of over 80 reference laboratories that perform a wide array of complex tests beyond the capabilities of in-clinic instruments.⁷ This service provides veterinarians with a comprehensive diagnostic menu, from routine pathology to advanced molecular testing. This line grew 5% organically in Q2 2025, reflecting some of the broader market softness in visit volumes but still demonstrating solid underlying demand.⁵
• Rapid Assay Products: These are single-use, point-of-care tests, most notably the SNAP® brand (e.g., 4Dx® Plus test for vector-borne diseases). This product line has experienced recent headwinds, with a 3% organic revenue decline in Q2 2025.⁵ This is not a sign of competitive weakness but rather a successful strategic migration of testing volume onto the company’s instrument platforms, which offers a more comprehensive and higher-margin solution for the company.²

• CAG Diagnostics Capital – Instruments: This sub-segment involves the sale or placement of the “razors”—the analyzers themselves. While revenue can be more cyclical than consumables, instrument placements are a crucial leading indicator of future recurring revenue growth. Q2 2025 saw a remarkable 62% organic growth in this area, driven by the highly successful launch of the new IDEXX inVue Dx™ analyzer.⁵
• Veterinary Software, Services, and Diagnostic Imaging Systems: This includes Practice Management Software (PMS) and other digital health platforms. This segment is strategically vital as it integrates IDEXX’s diagnostic offerings directly into the clinic’s core operational workflow, further solidifying customer relationships. It has demonstrated consistent growth, with 9% organic growth in Q2 2025.⁵

Water Quality Products (WQP): A highly stable and profitable business that provides microbiological testing solutions for water safety.¹ While serving a different end market, it leverages IDEXX’s core competencies in diagnostics and generates consistent cash flow, posting a solid 8% organic growth in Q2 2025.⁵

Livestock, Poultry and Dairy (LPD): This segment provides diagnostic products and services for production animals, focusing on herd health, disease surveillance, and food safety.¹ It is a smaller and more cyclical part of the business, subject to factors like disease outbreaks and government programs, and grew 3% organically in Q2 2025.⁵

Other: This segment primarily consists of the human medical diagnostics business, OPTI Medical Systems, which provides point-of-care blood gas and electrolyte analyzers.⁹

The Razor/Razorblade Model in Practice

IDEXX has masterfully executed the classic “razor/razorblade” business model. The company places its diagnostic instruments (the “razors”) in veterinary clinics, often through flexible acquisition models, which then generates a long-tail stream of high-margin, recurring revenue from the necessary proprietary consumables (the “razorblades”).

The direct linkage between these two components is evident in recent financial results. In Q2 2025, the global installed base of IDEXX’s premium Catalyst chemistry analyzers grew by 6% year-over-year, while the premium hematology analyzer base grew by 7%.⁵ This steady expansion of the installed base directly fueled the exceptional 14% organic growth in VetLab consumables revenue during the same period.⁵ This model creates a powerful virtuous cycle: innovation in instrumentation, such as the new IDEXX inVue Dx™ analyzer, drives new placements. The 2,388 inVue Dx placements in Q2 2025 alone represent a significant expansion of the future consumable revenue base, providing high visibility into long-term growth.⁵

Quantifying the Moat: Customer Stickiness and Switching Costs

IDEXX’s competitive advantage, or “moat,” is exceptionally wide and durable, rooted in high switching costs and the power of its integrated platform.

• High Switching Costs: Once a veterinary practice commits to the IDEXX ecosystem, the barriers to switching to a competitor are formidable. These costs are not merely financial but also operational and clinical. A switch would entail significant capital outlay for new instruments, extensive staff retraining on different hardware and software interfaces, the operational disruption of implementing a new workflow, and the critical risk of losing seamless access to historical patient diagnostic data.
• The Integrated Ecosystem: IDEXX’s most powerful competitive advantage is its fully integrated suite of solutions. A veterinarian can run a chemistry panel on a Catalyst analyzer, send a sample to an IDEXX reference lab for a more esoteric test, and have all results automatically and seamlessly populate the patient’s electronic medical record within the IDEXX practice management software. This deep, vertical integration creates a streamlined, efficient workflow that is difficult for competitors offering standalone products to replicate. It embeds IDEXX into the very fabric of a clinic’s daily operations, making the platform indispensable.
• Direct Commercial Model: Unlike some competitors who rely on third-party distributors, IDEXX employs a direct sales, service, and support force. This model fosters deep, consultative relationships with veterinary practices. IDEXX’s field representatives not only sell products but also provide training, technical support, and business consulting, positioning the company as a long-term partner rather than just a supplier. This high-touch approach builds immense loyalty and further increases customer stickiness.

The recent decline in Rapid Assay product sales provides a clear example of how IDEXX strengthens its moat over time. While on the surface a revenue decline may seem negative, it is a strategically positive development. Management has confirmed that this trend is partly driven by customers shifting specific tests, such as for pancreatic lipase, from a single-use rapid test to a more comprehensive panel on the Catalyst instrument platform.² This transition is highly beneficial for IDEXX. It moves revenue from a standalone, lower-margin product to a recurring, high-margin consumable stream that is locked into its proprietary instrument ecosystem. This “cannibalization” is a sign of successful upselling and platform entrenchment, ultimately improving the company’s margin profile and making its customer relationships even stickier.

II. Industry Analysis: Riding Powerful Secular Tailwinds

IDEXX operates within the large, growing, and resilient global veterinary diagnostics market. The industry is underpinned by one of the most powerful and durable consumer trends of the last two decades: the humanization of pets. This fundamental shift in the human-animal bond provides a powerful secular tailwind that drives demand for IDEXX’s products and services, insulating the industry from typical economic cycles.

The Global Veterinary Diagnostics Market: Sizing the Opportunity

The market for veterinary diagnostics is substantial and poised for sustained growth. Market research estimates for the global market size in 2025 range from approximately $8.7 billion to $11.8 billion.¹² Looking forward, a strong consensus projects the market to expand at a compound annual growth rate (CAGR) of between 7.8% and 11.5% through the next decade, providing a robust backdrop for IDEXX’s continued expansion.¹²

Key characteristics of the market include:

• Geographic Mix: North America is the largest and most developed market, accounting for approximately 38% to 49% of the global total, driven by high pet ownership, advanced veterinary infrastructure, and high per-pet spending.¹² However, the Asia-Pacific region is consistently identified as the fastest-growing market, presenting a significant long-term opportunity for international expansion.¹⁴
• Animal Type Mix: The companion animal segment is the primary driver of the market, representing approximately 60% of total diagnostic spending.¹⁴ This aligns perfectly with IDEXX’s strategic focus on its CAG business.
• Product Mix: Consumables, reagents, and kits constitute the largest product segment, accounting for over half of the market, underscoring the importance of the recurring revenue models employed by industry leaders.¹⁴

The Humanization of Pets: The Primary Demand Driver

The single most important trend fueling the veterinary diagnostics market is the “humanization of pets.” This refers to the societal shift from viewing pets as animals to treating them as integral family members, a transition from “pet ownership” to “pet parenthood”.²⁰ This emotional bond has profound economic consequences:

• Explosive Spending Growth: This trend has directly translated into a surge in spending on pet care. Global pet care sales reached an estimated $197.6 billion in 2023, while U.S. pet industry expenditures are projected to reach $157 billion in 2025.²³
• Premiumization of Care: As “pet parents,” owners are increasingly demanding a standard of medical care for their pets that mirrors human healthcare. This fuels a trend of “premiumization,” where owners opt for higher-quality, more sophisticated products and services, including advanced diagnostics, specialized diets, and cutting-edge therapeutics.²⁰
• Inelastic Demand: The emotional connection to pets makes spending on their health and well-being highly inelastic. Pet owners have consistently shown a willingness to cut back on personal discretionary spending before compromising on care for their animal companions, making the sector exceptionally resilient to economic downturns.²⁰

Competitive Landscape: A Tripartite Battleground

The veterinary diagnostics market is highly concentrated and dominated by three major players, creating a competitive oligopoly:

• IDEXX Laboratories (IDXX): The clear market leader, with an estimated market share of nearly 50% in the overall veterinary diagnostics space.²⁵ Its primary competitive advantage is its deeply integrated ecosystem of point-of-care analyzers, a global reference lab network, and practice management software.
• Zoetis (ZTS): A global powerhouse in animal health, primarily known for its pharmaceuticals and vaccines. Zoetis has become a formidable competitor in diagnostics, particularly following its strategic acquisition of Abaxis, a key player in in-clinic chemistry analyzers.²⁵ Zoetis is leveraging its extensive commercial relationships and R&D capabilities to challenge IDEXX, recently launching innovative products like the AI-powered Vetscan OptiCell hematology analyzer.¹⁷
• Mars, Incorporated (Private): As a private entity, Mars is a less visible but equally powerful force in the industry. Through a series of major strategic acquisitions, it has built a vertically integrated veterinary health empire. Its key assets include Antech Diagnostics, a major competitor to IDEXX in the reference laboratory space; VCA Animal Hospitals, one of the largest chains of veterinary clinics in North America and a massive end-user of diagnostic products; and, most recently, Heska Corporation, a direct competitor to IDEXX and Zoetis in the in-clinic instrument market.²⁴

This landscape creates a complex dynamic where Mars is simultaneously one of IDEXX’s largest potential customers (through its hospital chains) and one of its fiercest competitors (through Antech and Heska).

Barriers to Entry: A Formidable Fortress

The veterinary diagnostics market is protected by significant barriers to entry, which favor established incumbents and limit the threat from new entrants:

• Technological and R&D Intensity: Developing and manufacturing accurate, reliable, and user-friendly diagnostic instruments and assays requires substantial investment in research and development, deep scientific expertise, and a portfolio of intellectual property.
• The Power of the Installed Base: IDEXX’s massive global installed base of instruments creates a powerful network effect. It is a physical manifestation of its market share that is exceptionally difficult for a new entrant to replicate. This base provides a captive, recurring, and highly profitable stream of consumable revenue.
• Global Distribution and Support Network: Building a direct sales, service, and support infrastructure on a global scale is a capital-intensive and time-consuming endeavor. The established networks of IDEXX and Zoetis provide a significant competitive advantage in reaching and supporting veterinary clinics worldwide.
• Regulatory Hurdles: Gaining regulatory approval for new diagnostic tests and instruments in major markets like the U.S., Europe, and Asia is a complex, costly, and lengthy process that requires significant expertise and resources.⁹

The ongoing consolidation of veterinary practices by large corporate groups, such as Mars/VCA, presents a nuanced challenge that ultimately reinforces the strength of IDEXX’s moat. While the 10-K filing rightly identifies customer consolidation as a risk due to the increased negotiating power of these large entities ⁹, this trend also plays to IDEXX’s core strengths. These corporate owners are intensely focused on standardizing the quality of care, improving operational efficiency, and maximizing productivity across their vast networks of hospitals. IDEXX’s fully integrated platform—linking instruments, reference labs, and software—is uniquely positioned to deliver on these objectives by streamlining workflows and providing superior data integration. Therefore, even if a competitor offers a lower price on an instrument, the total cost of ownership for a large hospital group—factoring in training, workflow disruption, and the loss of data integration—could make switching away from IDEXX’s superior ecosystem an economically irrational decision. This dynamic transforms a potential pricing threat into a powerful demonstration of the moat’s resilience.

III. Financial Deep Dive: A Profile of Profitability and Scalability

IDEXX Laboratories exhibits a financial profile characterized by consistent growth, best-in-class profitability, and robust cash flow generation. The company’s scalable business model provides significant operating leverage, allowing for sustained margin expansion and the creation of exceptional long-term shareholder value.

Multi-Year Revenue & Margin Analysis

An examination of IDEXX’s financial performance over the past several years reveals a consistent and durable growth trajectory. The company has reliably delivered high-single-digit to low-double-digit organic revenue growth, driven primarily by the strength of its core CAG segment. This resilience was evident through the COVID-19 pandemic and the subsequent period of high inflation. Following a strong performance in the first half of 2025, the company raised its full-year organic revenue growth guidance to a range of 7.0% to 9.0%, underscoring its confidence in continued momentum.³

The company’s profitability is a key differentiator. IDEXX maintains a remarkably high and stable margin profile. In Q2 2025, the company reported a gross margin of 62.6% and a comparable operating margin of 33.6%, figures that place it in the upper echelon of the healthcare technology and diagnostics industries.³

The following table summarizes key financial metrics, providing a multi-year overview of the company’s performance and illustrating the durable trends in growth and profitability.

Metric	2019	2020	2021	2022	2023	2024	2025E
Total Revenue ($M)	$2,407	$2,707	$3,215	$3,367	$3,663	$3,900	$4,205 – $4,280
Organic Growth %	9.5%	11.0%	16.0%	6.0%	9.0%	7.5%	7.0% – 9.0%
CAG Revenue ($M)	$2,122	$2,423	$2,898	$3,043	$3,318	$3,541	N/A
Organic Growth %	10.5%	12.5%	18.0%	6.0%	9.0%	7.0%	5.8% – 8.0% (Recurring)
Gross Margin %	56.4%	57.6%	59.5%	59.0%	59.9%	60.8%	~62.0%
Operating Margin %	24.2%	25.5%	28.6%	26.6%	28.0%	29.0%	31.3% – 31.6%
Net Income ($M)	$401	$582	$749	$689	$845	$888	N/A
Diluted EPS ($)	$4.64	$6.71	$8.65	$8.01	$9.95	$10.77	$12.40 – $12.76
Cash Flow from Ops ($M)	$486	$684	$792	$675	$877	$906	95%-105% of NI
FCF Conversion %	~75%	~90%	~80%	~70%	~85%	~80%	80% – 85%

Note: Data for 2019-2024 is based on historical SEC filings and company reports. 2025E figures are based on updated company guidance as of August 4, 2025.³ Historical organic growth figures are illustrative based on company disclosures.

Unpacking the Margin Story

IDEXX’s best-in-class margin profile is not accidental but the result of several structural advantages and deliberate strategic initiatives:

• Favorable Business Mix: The primary driver of gross margin expansion is the continuous mix shift toward higher-margin revenue streams. The VetLab consumables business, which carries the highest gross margins, is consistently growing faster than the rest of the company, thereby lifting the overall margin profile.
• Durable Pricing Power: The non-discretionary nature of pet healthcare, amplified by the humanization trend, provides IDEXX with significant pricing power. The company has demonstrated its ability to implement annual price increases that effectively offset inflationary cost pressures on labor and raw materials.²
• Operational Excellence and Productivity: Management consistently highlights productivity initiatives, particularly within its global reference laboratory network, as a key contributor to both gross and operating margin gains.³
• Scalability and Operating Leverage: The business model is inherently scalable. As the installed base of instruments grows, the incremental revenue generated from each additional consumable sale comes with very low incremental costs. This allows profits to grow at a faster rate than revenue, a clear demonstration of operating leverage. This was evident in Q2 2025, where 9% organic revenue growth translated into a more impressive 14% comparable operating profit growth.²⁹

A Powerful Cash Flow Engine

IDEXX is a prolific cash flow generator, a hallmark of a high-quality business. In the first quarter of 2025 alone, the company generated $238.0 million in net cash from operating activities.² Management provides guidance for a full-year 2025 free cash flow (FCF) conversion rate of 80% to 85% of net income.⁴ This is a robust metric that indicates earnings are of high quality and are readily converted into cash, which can then be reinvested in the business or returned to shareholders. The company’s ability to consistently convert a high percentage of its accounting profits into cash underscores the efficiency and capital-light nature of its business model.

IV. Navigating the Macro Environment: Resilience in the Face of Headwinds (2023-2025)

The period from 2023 through 2025 has presented a challenging macroeconomic backdrop for the veterinary industry, characterized by persistent inflation, labor constraints, and a normalization of demand following the COVID-19-era pet adoption boom. However, IDEXX’s performance through this period has demonstrated the profound resilience of its business model and has, in many ways, reinforced the long-term investment thesis.

The Paradox of Visits and Revenue

Multiple data sources confirm that veterinary practices have experienced a decline in patient visit volumes through 2023 and 2024, as economic pressures led some pet owners to defer or forgo routine care.³⁰ IDEXX’s own industry data for Q2 2025 showed that same-store clinical visits in the U.S. were down 2.5% year-over-year.⁶

This decline in foot traffic, however, did not translate into a decline in revenue for either veterinary practices or for IDEXX. In fact, the data reveals a critical divergence that sits at the heart of the investment thesis: while visits fell, the value generated per visit increased significantly. In Q2 2025, while clinical visits declined by 2.5%, the diagnostic revenue per clinical visit surged by 6.5%.⁶ This resulted in overall diagnostic revenue growth for practices and fueled IDEXX’s strong 7% organic growth in its core CAG Diagnostics recurring revenue.³ This dynamic powerfully illustrates the inelastic demand for a higher standard of care and the success of IDEXX’s strategy to embed more comprehensive diagnostics into routine veterinary medicine.

Impact of Inflation and Labor Constraints

The veterinary industry has not been immune to broader economic challenges. Veterinary service inflation has consistently outpaced the national average, increasing the cost of care for pet owners.³⁰ Simultaneously, a well-documented shortage of veterinarians and veterinary technicians has constrained clinic capacity and driven up labor costs.¹⁵

These headwinds, while creating challenges for clinic operators, have also served as a powerful catalyst for the adoption of IDEXX’s most advanced technologies. Veterinary practices are facing a dual squeeze of lower patient volume and higher operating costs. To preserve their own profitability, they must focus on two key objectives: increasing the revenue generated from each patient visit and improving the productivity and efficiency of their staff.

IDEXX’s innovation pipeline is directly aimed at solving these problems. The new IDEXX inVue Dx™ Cellular Analyzer, for example, automates previously manual and time-consuming tasks like ear cytology and blood morphology analysis.³³ By doing so, it frees up valuable technician time—directly addressing the labor shortage—while simultaneously allowing the clinic to offer a new, high-value diagnostic service that increases revenue per visit. The exceptionally strong demand for this new platform, with 2,388 placements in a single quarter, suggests that the current macroeconomic pressures are compelling clinics to invest in efficiency-enhancing technology.⁵ This dynamic makes IDEXX’s growth more resilient during periods of economic softness than might be expected, as its products become essential tools for its customers to navigate their own business challenges.

V. Future Growth Vectors & Strategic Initiatives

While IDEXX is already a mature and dominant player, it has multiple well-defined vectors for sustained long-term growth. These initiatives are centered on a powerful innovation pipeline, strategic international expansion, and the continued development of its digital ecosystem.

The Innovation Pipeline: A New Wave of Growth Platforms

IDEXX’s R&D engine is the cornerstone of its growth strategy, consistently producing new technologies that expand the diagnostic menu, improve clinical outcomes, and enhance workflow efficiency. Two recent launches are poised to be significant growth drivers:

• IDEXX inVue Dx™ Cellular Analyzer: This is a major new point-of-care platform that represents a new era in in-clinic diagnostics. It is a “slide-free, AI-powered device” that delivers lab-quality results for cytology and blood morphology in approximately 10 minutes.¹⁷ The initial launch focuses on high-volume applications like ear cytology and blood analysis, which benefit immensely from automation and improved consistency.³³ The market reception has been overwhelmingly positive, with nearly 1,600 pre-orders by the end of 2024 and an exceptional 2,388 placements in Q2 2025 alone.⁵ The strength of this launch was a key reason for the company’s decision to raise its full-year 2025 revenue guidance.³
• IDEXX Cancer Dx™: This is a potentially transformative new product line that addresses one of the most significant areas of unmet need in veterinary medicine. It is a first-of-its-kind diagnostic panel for the early detection of cancer in dogs, with the initial launch in 2025 focused on lymphoma.³³ Over the subsequent three years, the panel is planned to expand to include the six most prevalent canine cancers, which collectively account for over half of all cancer cases in dogs. The company has estimated the total addressable market opportunity for this panel at
  $1.1 billion, representing a substantial new layer of potential growth that is not yet fully reflected in consensus estimates.³³

International Expansion: Tapping into Underpenetrated Markets

IDEXX has a significant runway for growth outside of the United States. Management has identified that approximately two-thirds of the total global addressable market for companion animal diagnostics lies in international regions.³⁶ The standard of care and diagnostic utilization in many of these markets lag behind the U.S., presenting a long-term opportunity for penetration and growth.

The company is strategically investing to enhance its commercial capabilities in key international markets, including expanding its direct sales force in countries like Germany and France.³⁷ This strategy is bearing fruit, as evidenced by the strong double-digit (11% organic) growth in international CAG Diagnostics recurring revenue in Q2 2025—a rate nearly double that of the more mature U.S. market.³

The Digital Frontier: Software, Data Analytics, and AI

The integration of digital technology is a key component of IDEXX’s strategy to deepen its moat.

• Software and Services: The company’s practice management software (PMS) is a critical anchor in its ecosystem. By managing a clinic’s appointments, billing, and electronic medical records, the PMS becomes the central nervous system of the practice. The seamless integration of IDEXX’s diagnostic results into its PMS creates a superior workflow that is difficult for competitors to match. Management sees the potential for this business to grow at a rate of 15% or more per year.³⁶
• Artificial Intelligence (AI): AI is becoming a core enabling technology across the industry. IDEXX is at the forefront of this trend, embedding AI and machine learning algorithms into its platforms, such as the inVue Dx analyzer, to automate processes and improve diagnostic accuracy.¹⁵
• Data as an Asset: IDEXX’s vast and growing repository of diagnostic data, collected from its global network of reference labs and millions of in-clinic analyzers, represents a significant and underappreciated strategic asset. This proprietary dataset can be leveraged to train more sophisticated AI models, identify disease trends, and develop novel diagnostic insights, creating a data-driven competitive advantage that will be increasingly difficult for others to replicate.

VI. Capital Allocation Framework & Shareholder Return Strategy

IDEXX employs a disciplined and shareholder-friendly capital allocation strategy focused on reinvesting in high-return organic growth initiatives while consistently returning excess capital to shareholders through a robust share repurchase program. The company’s strong balance sheet and prodigious cash flow generation provide significant flexibility to execute this strategy.

Share Repurchase Program

IDEXX does not currently pay a dividend, choosing instead to return capital to shareholders primarily through share repurchases.³⁹ This has been a consistent and significant part of the company’s capital allocation framework. In the first quarter of 2025 alone, the company deployed $400.9 million to repurchase its common stock.² The company maintains an active share repurchase authorization from its Board of Directors and has a stated goal of reducing its average shares outstanding by 2% to 3% in 2025.⁴ This programmatic approach to buybacks provides a steady source of demand for the stock and is accretive to earnings per share over the long term.

Debt Management and Capital Structure

The company maintains a strong and flexible balance sheet. As of the end of the second quarter of 2025, leverage ratios were modest, with a gross debt-to-EBITDA ratio of 0.8x and a net ratio of 0.6x after accounting for cash on hand.²⁹ The capital structure includes a $1.25 billion revolving credit facility and a series of privately placed senior notes.² The company actively manages its interest rate risk; for example, it has utilized an interest rate swap to effectively fix the rate on $250 million of its variable-rate borrowings, mitigating the impact of rising rates.² This prudent approach to leverage ensures the company has ample financial capacity to fund its growth initiatives and navigate any potential economic downturns.

Capital Expenditures and Return on Invested Capital (ROIC)

IDEXX’s business model is relatively capital-light, which contributes to its exceptional returns. For the full year 2025, the company projects capital expenditures of approximately $160 million.⁵ This level of investment is modest when compared to the company’s operating cash flow, allowing for significant free cash flow generation.

The combination of high profitability and low capital intensity results in outstanding returns on invested capital. Recent analyses indicate the company generates a Return on Invested Capital (ROIC) of approximately 29.4% and a Return on Equity (ROE) of nearly 65%.⁴⁰ These are elite figures that demonstrate highly efficient and effective capital management and are a key reason the business commands a premium valuation.

VII. Valuation Analysis: Deconstructing a Premium Multiple

IDEXX Laboratories has historically and consistently traded at a premium valuation relative to the broader market and its direct peers. This premium is a direct reflection of its superior business model, dominant market position, high and defensible margins, and consistent growth profile. While the absolute valuation multiples are high, a detailed analysis suggests they are justified by the quality and durability of the earnings stream.

Historical Valuation Context

As of late August 2025, IDEXX’s stock trades at a trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio of approximately 53x.⁴⁰ While this appears high in isolation, it is remarkably consistent with the company’s 10-year average P/E ratio of 53.0x, indicating that the current valuation is in line with its long-term historical norm.⁴²

The Enterprise Value to EBITDA (EV/EBITDA) multiple provides a similar picture. The current TTM EV/EBITDA multiple is approximately 33-37x.⁴⁰ This is below the company’s 5-year average of 43.3x and well below its peak of 59.3x reached in 2020, but has recovered from the 5-year low of 26.6x seen in 2024.⁴⁴ This suggests that while the valuation has rebounded from recent macroeconomic concerns, it is not in excessively expensive territory relative to its own history.

Peer Benchmarking

A comparison to peers is essential to contextualize IDEXX’s valuation.

Metric	IDEXX (IDXX)	Zoetis (ZTS)	Thermo Fisher (TMO)	Intuitive Surgical (ISRG)
Market Cap ($B)	~$51B	~$68B	~$185B	~$168B
EV/Sales (LTM)	~12.8x	~7.8x	~4.5x	~12.0x
EV/EBITDA (LTM)	~37.2x	~18.5x – 20.9x	~17.0x	~35.0x
P/E (LTM)	~52.8x	~25.9x – 26.2x	~22.5x	~70.3x
LTM Revenue Growth	~6.5%	~7.0%	~-5.0%	~12.0%
LTM Gross Margin	~61.5%	~70.0%	~42.0%	~66.0%
LTM Operating Margin	~31.1%	~37.0%	~19.0%	~28.0%
ROIC	~29.4%	~25.0%	~7.0%	~20.0%

Note: Valuation metrics are as of late 2025 and are sourced from a combination of financial data providers.⁴⁰ Peer data is for comparative purposes.

The table clearly illustrates the valuation premium IDEXX commands over its closest competitor, Zoetis. Zoetis trades at a P/E of ~26x and an EV/EBITDA of ~21x, significantly lower than IDEXX.⁴⁵ This discount is attributable to Zoetis’s different business mix, which includes a larger, lower-margin, and more capital-intensive pharmaceutical and vaccine business. IDEXX’s premium is justified by its higher concentration in the faster-growing, higher-margin diagnostics segment with its highly recurring revenue model. When benchmarked against other best-in-class, high-margin med-tech leaders like Intuitive Surgical, IDEXX’s valuation appears more reasonable.

Scenario Analysis and Intrinsic Value

A discounted cash flow (DCF) analysis can provide a framework for assessing intrinsic value under various scenarios:

• Base Case: This scenario assumes revenue growth and margin expansion consistent with current company guidance and long-term targets, such as the 10%+ long-term organic revenue growth potential mentioned by management.³⁶ This would likely yield an intrinsic value that supports the current share price, suggesting the stock is fairly valued given its prospects.
• Bull Case: This scenario would model faster-than-expected adoption of new platforms like Cancer Dx, leading to accelerated revenue growth and margin expansion. It would also assume greater success in international market penetration. This scenario would suggest the stock is undervalued.
• Bear Case: This scenario assumes persistent macroeconomic pressures lead to a prolonged decline in clinic visits, limiting pricing power. It would also factor in greater-than-expected market share gains by competitors like Zoetis. This scenario would suggest the stock is overvalued.

Given the company’s track record of execution and the resilience demonstrated through recent headwinds, the base case appears the most probable, with a positive skew toward the bull case driven by the innovation pipeline.

Final Assessment: A Justified Premium

While IDEXX’s valuation multiples are objectively high, they are not unreasonable when considering the company’s exceptional quality. The premium is a function of its superior financial characteristics—including high ROIC, robust free cash flow conversion, and a highly scalable business model—combined with its durable competitive advantages and exposure to powerful, non-discretionary secular growth trends. The market is willing to pay a premium for the certainty, durability, and quality of IDEXX’s earnings stream.

VIII. Management Quality & Corporate Governance

The long-term success of any company is intrinsically linked to the quality of its leadership and the soundness of its governance practices. IDEXX benefits from an experienced executive team with a strong track record of execution and a well-structured, independent board of directors.

Executive Team and Track Record

• Jonathan (Jay) Mazelsky, President and CEO: Mr. Mazelsky has served as CEO since 2019, having previously held other executive roles at the company.⁵⁰ Under his leadership, IDEXX has successfully navigated the COVID-19 pandemic and subsequent macroeconomic challenges while continuing to deliver strong financial results and advance its innovation pipeline. His commentary on earnings calls and investor presentations demonstrates a clear strategic focus on the central role of diagnostics in elevating the standard of pet care, which aligns perfectly with the company’s core growth drivers.⁶
• CFO Transition: The company has announced a well-planned CFO transition for 2025. Brian McKeon, the respected and long-tenured CFO since 2014, is set to retire.⁵⁰ He will be succeeded by Andrew Emerson, a nine-year IDEXX veteran who currently leads finance for the CAG business and the corporate finance function.⁵³ This internal promotion ensures continuity and a deep understanding of the company’s strategy and financial operations, minimizing transition risk.
• Broader Leadership Team: The executive team is composed of seasoned leaders with extensive experience from major global healthcare, technology, and consumer companies, including Abbott Laboratories, Novartis, and Pepsi-Cola.⁵⁰ This depth of experience is crucial for managing a complex global organization and driving its innovation agenda.

Board of Directors and Corporate Governance

IDEXX’s corporate governance structure appears robust and aligned with shareholder interests.

• Board Composition and Independence: As of July 2025, the Board of Directors comprises ten members, nine of whom are classified as independent.⁵⁷ This high degree of independence is a hallmark of good corporate governance. The Chairman of the Board, Lawrence D. Kingsley, is also independent.⁵¹
• Relevant Expertise: The board is composed of individuals with deep and relevant experience in finance, healthcare, and technology. Members include former CEOs and senior executives from companies such as Pall Corporation, State Street Corporation, Quest Diagnostics, Integra LifeSciences, and Campbell Soup Company.⁵⁶ This diversity of expertise is invaluable for providing strategic oversight.
• Shareholder Alignment: While insider ownership is relatively low at approximately 1% ⁴⁰, alignment is primarily achieved through equity-based compensation programs for executives and directors, as detailed in the company’s annual proxy statement.³³ The company is also responsive to shareholder feedback, as evidenced by recent proxy votes to declassify the board and remove supermajority voting provisions.⁶⁰

IX. Risk Factors

An investment in IDEXX Laboratories is subject to a number of risks that could materially affect its business, financial condition, and stock price. These risks, detailed in the company’s annual 10-K filing, span economic, competitive, regulatory, and operational domains.⁹

Economic and Market Risks

• Economic Cycles and Consumer Spending: A severe or prolonged global recession could significantly reduce discretionary income, leading pet owners to defer or forgo veterinary visits and diagnostic testing. While the business has proven resilient, it is not immune to a major economic contraction.⁹
• Foreign Exchange Risk: With a significant portion of its revenue generated outside the United States, a strengthening U.S. dollar can negatively impact reported revenues and profits.⁹
• Customer Consolidation: The increasing consolidation of veterinary practices into large corporate groups could increase their purchasing power, leading to pricing pressure on IDEXX’s products and services.⁹

Competitive and Technology Risks

• Intense Competition: IDEXX faces intense competition from well-capitalized and sophisticated competitors, namely Zoetis and Mars (Antech/Heska). Aggressive product launches or pricing strategies from these competitors could impact IDEXX’s market share and profitability.⁹
• Technology Disruption: The field of diagnostics is subject to rapid technological change. A new entrant with a disruptive technology could potentially render parts of IDEXX’s current platform obsolete. Additionally, the increasing use of AI introduces risks related to flawed algorithms or datasets.⁹
• Changes in Testing Patterns: The introduction of new vaccines or therapeutics that prevent or cure common diseases could reduce the long-term demand for related diagnostic tests.⁹

Regulatory and Operational Risks

• Government Regulation: The company’s products are subject to extensive and complex regulations by the USDA, FDA, and international agencies. Delays in product approvals or changes in regulatory requirements could increase costs and hinder growth.⁹
• Supply Chain Dependence: IDEXX relies on third-party suppliers for certain raw materials and components. Disruptions to this supply chain due to geopolitical events, natural disasters, or supplier-specific issues could interrupt manufacturing and impact sales.⁹
• Cybersecurity Threats: As a technology-driven company, IDEXX is dependent on its IT systems and is a target for cybersecurity threats. A significant data breach or system disruption could have a material adverse effect on operations and reputation.⁹
• Execution Risk: The investment thesis relies on the successful commercialization of new products in the pipeline, such as Cancer Dx, and the continued flawless execution of the company’s international expansion and commercial strategies.

X. Conclusion: Answering the Key Investor Questions

This comprehensive analysis culminates in direct, thesis-driven answers to the key strategic questions facing investors considering an investment in IDEXX Laboratories.

1. How sustainable is IDEXX’s premium valuation given industry headwinds?

The premium valuation is sustainable for long-term investors. The recent industry headwinds, particularly the moderation in clinic visit growth, have paradoxically served to prove the durability and resilience of IDEXX’s business model. The company has demonstrated a clear ability to grow through these challenges by increasing diagnostic utilization per visit, a direct result of the powerful “humanization of pets” trend and the rising standard of care. The valuation premium is not based on cyclical growth but on superior and durable financial characteristics: best-in-class profitability, high return on invested capital, robust free cash flow generation, and a formidable competitive moat built on high switching costs and an integrated ecosystem. The current valuation is in line with the company’s own historical averages, reflecting the market’s consistent willingness to pay a premium for this level of quality.

2. Can the company maintain its historically strong margin profile in a challenging environment?

Yes, the company is well-positioned not only to maintain but to continue expanding its margin profile. Margin expansion is a core component of the investment thesis, supported by several key drivers. First, the ongoing business mix shift toward higher-margin VetLab consumables, which are growing faster than the overall business, provides a structural tailwind to gross margins. Second, the company’s scalable business model creates significant operating leverage, allowing profits to grow faster than revenue as the installed base expands. Third, the introduction of new, high-value premium tests, such as the forthcoming Cancer Dx panel, will carry high margins and further enhance profitability. The company’s updated 2025 guidance, which calls for 50 to 80 basis points of comparable operating margin expansion, explicitly supports this outlook.⁴

3. What are the most significant growth catalysts for the next 3-5 years?

The most significant growth catalysts are rooted in the company’s innovation pipeline and strategic expansion initiatives:

• Platform Innovation: The full commercial rollout and subsequent menu expansion of the new IDEXX inVue Dx™ Cellular Analyzer platform is the most significant near-term catalyst. The early success of this launch is already contributing to upside revenue revisions.
• New Testing Paradigms: The launch and adoption of the IDEXX Cancer Dx™ panel represents a multi-year growth opportunity in a large, untapped market. This moves IDEXX further into the high-value realm of early detection and disease management.
• International Expansion: Continued penetration of under-served international markets, where diagnostic utilization is lower than in the U.S., provides a long runway for growth. The company’s focused commercial investments in these regions are already yielding double-digit growth rates.
• Digital Ecosystem: The continued development and integration of the company’s software, data analytics, and telemedicine offerings will further deepen its competitive moat and create new revenue opportunities.

4. How well-positioned is IDEXX to benefit from long-term trends in pet ownership and veterinary care?

IDEXX is arguably the single best-positioned public company to benefit from these powerful secular trends. Its entire business model is built around capitalizing on the “humanization of pets” and the corresponding demand for a higher standard of medical care. As “pet parents” become more willing to spend on their pets’ health, the demand for more comprehensive and sophisticated diagnostics—the core of IDEXX’s business—will continue to rise. The company’s innovation pipeline is directly aligned with this trend, continuously providing veterinarians with new tools to practice a higher quality of medicine that meets the evolving expectations of their clients.

5. What are the key metrics investors should monitor to assess the investment thesis?

To track the health and progress of the investment thesis, investors should focus on the following key performance indicators:

• CAG Diagnostics Recurring Revenue Organic Growth: This is the single most important top-line metric, as it represents the growth of the company’s core, high-margin, recurring business.
• Premium Instrument Placements: This is the key leading indicator of future recurring consumable revenue growth. Particular attention should be paid to the placement numbers for new platforms like the inVue Dx.
• Comparable Operating Margin Expansion: This metric is the clearest indicator of the company’s ability to generate operating leverage and improve profitability over time.
• Free Cash Flow Conversion: This metric serves as a crucial check on the quality of earnings and the capital efficiency of the business model.
• Diagnostic Utilization per Clinic Visit: In the current environment, this metric is vital for assessing the company’s ability to grow and demonstrate pricing power, even if overall clinic visit growth remains modest.

Works cited

1. IDEXX Laboratories (IDXX) Investor Relations Material – Quartr, accessed September 4, 2025, https://quartr.com/companies/idexx-laboratories-inc_4846
2. IDEXX LABORATORIES, INC., accessed September 4, 2025, https://www.idexx.com/files/10q20250501.pdf
3. IDEXX Laboratories Announces Second Quarter Results – Veterinary 33, accessed September 4, 2025, https://www.veterinary33.com/public-health/latest-news/2542/idexx-laboratories-announces-second-quarter-results.html
4. 2025 Q2 Earnings Release – IDEXX.com, accessed September 4, 2025, https://www.idexx.com/files/2025-q2-earnings-release-20250804.pdf
5. IDEXX Q2 2025 Earnings Snapshot – IDXX, accessed September 4, 2025, https://www.idexx.com/files/earnings-snapshot-2025-q2.pdf
6. IDEXX Q2 2025 slides reveal 17% EPS growth, company raises full-year guidance, accessed September 4, 2025, https://www.investing.com/news/company-news/idexx-q2-2025-slides-reveal-17-eps-growth-company-raises-fullyear-guidance-93CH-4168296
7. About Us – IDEXX US, accessed September 4, 2025, https://www.idexx.com/en/about-idexx/
8. Finance Director, Investor Relations in Westbrook, ME | Corporate at IDEXX, accessed September 4, 2025, https://careers.idexx.com/us/en/job/J-047273/Finance-Director-Investor-Relations
9. Form 10-K – IDEXX.com, accessed September 4, 2025, https://www.idexx.com/files/10k20250221.pdf
10. 10-Q filed November 1, 2023 – Idexx, accessed September 4, 2025, https://www.idexx.com/files/10q20231101.pdf
11. 10-Q filed May 1, 2024 – Idexx, accessed September 4, 2025, https://www.idexx.com/files/10q20240501.pdf
12. Veterinary Diagnostics Market Share | Industry Report [2032] – Fortune Business Insights, accessed September 4, 2025, https://www.fortunebusinessinsights.com/industry-reports/veterinary-diagnostics-market-101040
13. Veterinary Diagnostics Market – Trends, Size & Companies – Mordor Intelligence, accessed September 4, 2025, https://www.mordorintelligence.com/industry-reports/veterinary-diagnostics-market
14. Veterinary Diagnostics Market Size to Hit USD 28.06 Billion by 2034 – Precedence Research, accessed September 4, 2025, https://www.precedenceresearch.com/veterinary-diagnostics-market
15. Global Veterinary Diagnostics Market Set to Reach USD 5.36 Billion by 2030 | MarketsandMarkets – GlobeNewswire, accessed September 4, 2025, https://www.globenewswire.com/news-release/2025/08/25/3138460/0/en/Global-Veterinary-Diagnostics-Market-Set-to-Reach-USD-5-36-Billion-by-2030-MarketsandMarkets.html
16. Veterinary Diagnostics Market Size, Share, Trends 2034 | MRFR, accessed September 4, 2025, https://www.marketresearchfuture.com/reports/veterinary-diagnostics-market-21729
17. Veterinary Diagnostics Market Size | Industry Report, 2030 – Grand View Research, accessed September 4, 2025, https://www.grandviewresearch.com/industry-analysis/veterinary-diagnostics-market
18. Veterinary Diagnostics Industry Growth News – $5.36B by 2030 – MarketsandMarkets, accessed September 4, 2025, https://www.marketsandmarkets.com/PressReleases/veterinary-diagnostics.asp
19. Animal Diagnostics Market Set for 10.2% CAGR Growth By 2034, accessed September 4, 2025, https://media.market.us/animal-diagnostics-market-news/
20. The Humanization of Pets: How Our Furry Friends Have Become Family, accessed September 4, 2025, https://clearlylovedpets.com/blogs/clearly-loved-pets-blog/the-humanization-of-pets
21. Humanisation pet economy Asia – Allianz Global Investors, accessed September 4, 2025, https://www.allianzgi.com/en/insights/outlook-and-commentary/humanisation-pets-asia
22. How humanizing pets is reshaping pet owners’ habits – Ipsos, accessed September 4, 2025, https://www.ipsos.com/en-us/future/how-humanizing-pets-reshaping-pet-owners-habits
23. Pet humanisation and premium products drive global pet care sales …, accessed September 4, 2025, https://www.euromonitor.com/press/press-releases/september-2024/pet-humanisation-and-premium-products-drive-global-pet-care-sales-up-by-5.9-to-usd197.6-billion-euromonitor-international
24. on Animal Diagnostics Market Size, Share | Industry Trend & Forecast 2031 – IndustryARC, accessed September 4, 2025, https://www.industryarc.com/PressRelease/4605/companion-animal-diagnostics-market
25. Veterinary Diagnostics: IDEXX, Mars Petcare, and Zoetis Driving 7% CAGR 2023-2028, accessed September 4, 2025, https://kaloramainformation.com/blog/veterinary-diagnostic-leaders/
26. Zoetis (ZTS) Investor Relations Material – Quartr, accessed September 4, 2025, https://quartr.com/companies/zoetis-inc_3924
27. Veterinary Chemistry Analyzer Market Size Report, 2030 – Grand View Research, accessed September 4, 2025, https://www.grandviewresearch.com/industry-analysis/veterinary-chemistry-analyzer-market
28. Mars Veterinary Health: Home, accessed September 4, 2025, https://marsveterinary.com/
29. Q2 Fiscal Year 2025 Earnings Call – Prepared Remarks – IDEXX.com, accessed September 4, 2025, https://www.idexx.com/files/2025-q2-prepared-remarks.pdf
30. Veterinary visits decline as clients face rising costs, data reveals – DVM360, accessed September 4, 2025, https://www.dvm360.com/view/veterinary-visits-decline-as-clients-face-rising-costs-data-reveals
31. 2024 Veterinary Stats – Otto, accessed September 4, 2025, https://otto.vet/2024-veterinary-stats/
32. Less foot traffic at veterinary practices spells declining revenue, accessed September 4, 2025, https://www.avma.org/news/less-foot-traffic-veterinary-practices-spells-declining-revenue
33. Preliminary Proxy Statement filed March 14, 2025 – Idexx, accessed September 4, 2025, https://www.idexx.com/files/preliminary-proxy-statement-filed-march-14-2025.pdf
34. What are the effects on the pet industry of inflation stabilization? – GlobalPETS, accessed September 4, 2025, https://globalpetindustry.com/article/what-are-the-effects-on-the-pet-industry-of-inflation-stabilization/
35. Petflation 2024 – December Update: Drops to +2.0% vs 2023 – Pet Business Professor, accessed September 4, 2025, https://petbusinessprofessor.com/petmarket/petmarketsegments/petflation-2024-december-update-drops-to-2-0-vs-2023/
36. IDEXX Investor Day 2025, accessed September 4, 2025, https://www.idexx.com/files/2025-08-14-idexx-investor-day.pdf
37. Notice of 2022 Annual Meeting of Shareholders & Proxy Statement – Idexx, accessed September 4, 2025, https://www.idexx.com/files/definitive-proxy-statement-filed-march-31-2022.pdf
38. Veterinary Diagnostics Market Growth, Drivers, and Opportunities – MarketsandMarkets, accessed September 4, 2025, https://www.marketsandmarkets.com/Market-Reports/veterinary-diagnostics-market-26017452.html
39. IDEXX Laboratories (IDXX) Stock Price & Overview, accessed September 4, 2025, https://stockanalysis.com/stocks/idxx/
40. IDEXX Laboratories (IDXX) Statistics & Valuation – Stock Analysis, accessed September 4, 2025, https://stockanalysis.com/stocks/idxx/statistics/
41. Investor relations – IDEXX US, accessed September 4, 2025, https://www.idexx.com/en/about-idexx/investors/
42. IDXX – Idexx Laboratories PE ratio, current and historical analysis – FullRatio, accessed September 4, 2025, https://fullratio.com/stocks/nasdaq-idxx/pe-ratio
43. IDEXX Laboratories PE Ratio 2010-2025 | IDXX – Macrotrends, accessed September 4, 2025, https://www.macrotrends.net/stocks/charts/IDXX/idexx-laboratories/pe-ratio
44. IDEXX Laboratories Inc (BIT:1IDXX) EV / EBITDA – Investing.com, accessed September 4, 2025, https://www.investing.com/pro/BIT:1IDXX/explorer/ev_to_ebitda_ltm
45. Zoetis Inc (ZTS) EV/EBITDA – Investing.com UK, accessed September 4, 2025, https://uk.investing.com/pro/FINBOX:ZTS/explorer/ev_to_ebitda_ltm
46. Zoetis EBITDA 2011-2025 | ZTS – Macrotrends, accessed September 4, 2025, https://www.macrotrends.net/stocks/charts/ZTS/zoetis/ebitda
47. Zoetis PE Ratio 2011-2025 | ZTS – Macrotrends, accessed September 4, 2025, https://www.macrotrends.net/stocks/charts/ZTS/zoetis/pe-ratio
48. ZTS – Zoetis PE ratio, current and historical analysis – FullRatio, accessed September 4, 2025, https://fullratio.com/stocks/nyse-zts/pe-ratio
49. Zoetis (NYSE:ZTS) Stock Valuation, Peer Comparison & Price Targets – Simply Wall St, accessed September 4, 2025, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-zts/zoetis/valuation
50. Idexx Laboratories Inc: Executives – GlobalData, accessed September 4, 2025, https://www.globaldata.com/company-profile/idexx-laboratories-inc/executives/
51. Who are in the management team of IDEXX Laboratories, Inc.? – MarketsMojo, accessed September 4, 2025, https://www.marketsmojo.com/news/stocks-in-action/who-are-in-the-management-team-of-idexx-laboratories-inc-3168421
52. Earnings call transcript: IDEXX Labs beats Q2 2025 expectations, stock surges, accessed September 4, 2025, https://www.investing.com/news/transcripts/earnings-call-transcript-idexx-labs-beats-q2-2025-expectations-stock-surges-93CH-4168045
53. IDEXX Announces CFO Transition, accessed September 4, 2025, https://www.idexx.com/en/about-idexx/news/idexx-announces-cfo-transition/
54. IDEXX Laboratories CEO and Key Executive Team – Craft.co, accessed September 4, 2025, https://craft.co/idexx-laboratories/executives
55. Leadership Team – Idexx Laboratories – The Org, accessed September 4, 2025, https://theorg.com/org/idexx-laboratories/teams/leadership-team
56. Corporate governance – IDEXX US, accessed September 4, 2025, https://www.idexx.com/en/about-idexx/corporate-governance/
57. 8-K filed July 10, 2025 – Idexx, accessed September 4, 2025, https://www.idexx.com/files/8k20250710.pdf
58. IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors, accessed September 4, 2025, https://www.idexx.com/en/about-idexx/news/idexx-elects-joseph-l-jay-hooley-to-board-of-directors/
59. Internet Availability of Proxy Materials, accessed September 4, 2025, https://www.idexxproxymaterials.com/
60. 8-K filed May 9, 2025 – IDEXX.com, accessed September 4, 2025, https://www.idexx.com/files/8k20250509.pdf
61. IDEXX Laboratories Inc. (via Public) / Proxy Results, Amendments to Bylaws (Form 8-K), accessed September 4, 2025, https://ebs.publicnow.com/view/5C840748A29F704D7C513E99025E579BA9109374